Post by Link Biologics

Following Reuben Dawkins' recognition as one of In Vivo's Rising Leaders, he recently spoke to Anabel Costa-Ferreira of Citeline about building Link Biologics. Reuben describes his role as a “catalyst” – bringing together the right science, people and direction to unlock real-world impact. This approach underpins #LinkBiologics and our work developing TSG-6-based therapies that harness and fine-tune the body's own anti-inflammatory and tissue reparative pathways. By combining deep academic expertise with a clear translational focus, Link is working to realise this therapeutic potential – starting with its first-in-class programme, #LB001, in #DryEyeDisease. 🔗 Read the full article in In Vivo: https://bit.ly/3SzqrAB #InVivosRisingLeaders2026 #Leadership #TSG6 #DryEyeDisease #Ophthalmology #LinkBiologics